ella

About Ella Korets-Smith

This author has not yet filled in any details.
So far Ella Korets-Smith has created 23 blog entries.

ADVANCED PROTEOME THERAPEUTICS REPORTS POSITIVE RESULTS AND ADVANCES COLLABORATION WITH HEIDELBERG PHARMA

2018-11-21T09:21:27+00:00

Vancouver, British Columbia / November 14, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens [...]

ADVANCED PROTEOME THERAPEUTICS REPORTS POSITIVE RESULTS AND ADVANCES COLLABORATION WITH HEIDELBERG PHARMA2018-11-21T09:21:27+00:00

ADVANCED PROTEOME THERAPEUTICS REPORTS PROGRESS ON COLLABORATION WITH NORIA PHARMACEUTICALS

2018-10-17T09:25:48+00:00

Vancouver, British Columbia / October 15, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce the successful completion of the first phase of the Collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing and dynamic field of antibody radioisotope conjugates which is expected to [...]

ADVANCED PROTEOME THERAPEUTICS REPORTS PROGRESS ON COLLABORATION WITH NORIA PHARMACEUTICALS2018-10-17T09:25:48+00:00

APC COMMENTS ON FAVOURABLE RESULTS IN INITIAL ANIMAL STUDIES

2018-10-17T09:24:16+00:00

Vancouver, British Columbia / October 9, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report favorable results in initial animal studies. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens. The combination of APC's proprietary [...]

APC COMMENTS ON FAVOURABLE RESULTS IN INITIAL ANIMAL STUDIES2018-10-17T09:24:16+00:00

ADVANCED PROTEOME THERAPEUTICS PROVIDES OVERVIEW OF CURRENT ACTIVITIES AND STRATEGIC OBJECTIVES

2018-09-19T09:11:57+00:00

Vancouver, British Columbia / September 11, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to provide an overview of current projects prior to more detailed news releases that will be disclosed shortly. Radioimmunoconjugates APC’s site-selective technology is being employed in the emergent field of radioimmunoconjugates (radioactive substances [...]

ADVANCED PROTEOME THERAPEUTICS PROVIDES OVERVIEW OF CURRENT ACTIVITIES AND STRATEGIC OBJECTIVES2018-09-19T09:11:57+00:00

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES COLLABORATION WITH NORIA PHARMACEUTICALS INC.

2018-07-19T11:15:51+00:00

Vancouver, British Columbia / July 17, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce the Collaboration  of APC with Noria Pharmaceuticals Inc. in the rapidly growing field of antibody radioisotope conjugates. APC will test its proprietary, site-selective, linker technology with Noria’s proprietary MacroPa radioisotope chelation [...]

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES COLLABORATION WITH NORIA PHARMACEUTICALS INC.2018-07-19T11:15:51+00:00

ADVANCED PROTEOME THERAPEUTICS ADVANCES ITS TECHNOLOGICAL CAPABILITY

2018-06-27T11:25:17+00:00

Vancouver, British Columbia / June 18, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report continuing progress on its efforts to develop superior antibody drug conjugates (ADCs). Proceeding from cytotoxicity studies to the next phase of testing in animals necessitates scaling up processes by a significant [...]

ADVANCED PROTEOME THERAPEUTICS ADVANCES ITS TECHNOLOGICAL CAPABILITY2018-06-27T11:25:17+00:00

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES APPOINTMENT OF BILL DICKIE AS CHIEF EXECUTIVE OFFICER AND DIRECTOR

2018-06-07T14:01:35+00:00

VANCOUVER, British Columbia, June 06, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8) is pleased to announce the appointment of Mr. Bill Dickie as Chief Executive Officer, President and Director of the company, effective June 6, 2018. Mr. Dickie brings with him more than 30 years of exceptionally qualified experience in [...]

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES APPOINTMENT OF BILL DICKIE AS CHIEF EXECUTIVE OFFICER AND DIRECTOR2018-06-07T14:01:35+00:00

ADVANCED PROTEOME THERAPEUTICS UPDATES ITS ACTIVITIES DURING THE 3RD QUARTER, FY 2018

2018-05-08T09:47:05+00:00

Vancouver, British Columbia / May 1, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to provide an update of progress during the third quarter, FY 2018. The Company, in its pursuit of commercial success is vigourously applying innovative core principles ((Marketwired - January 31, 2018) to advance [...]

ADVANCED PROTEOME THERAPEUTICS UPDATES ITS ACTIVITIES DURING THE 3RD QUARTER, FY 20182018-05-08T09:47:05+00:00

ADVANCED PROTEOME ANNOUNCES APPOINTMENT OF SCIENTIFIC ADVISORY BOARD MEMBERS

2018-04-29T21:59:00+00:00

Vancouver, British Columbia / April 24, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce the appointments of two new members to its Scientific Advisory Board (SAB):  Dr. Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital Cancer Center (MGHCC), Harvard Medical [...]

ADVANCED PROTEOME ANNOUNCES APPOINTMENT OF SCIENTIFIC ADVISORY BOARD MEMBERS2018-04-29T21:59:00+00:00

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES APPOINTMENT OF NEW BOARD MEMBERS

2018-04-29T21:56:42+00:00

Vancouver, British Columbia / April 16, 2018– Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce the appointments of Dr. John R. Garrett and Paul Woodward to its Board of Directors. Dr. Garrett is a Principal of John Garrett & Partners with a practice focusing on early stage US and [...]

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES APPOINTMENT OF NEW BOARD MEMBERS2018-04-29T21:56:42+00:00